Humacyte (HUMA) director now holds 40,000 shares after buy
Rhea-AI Filing Summary
Humacyte, Inc. (HUMA) director Keith Anthony Jones reported purchasing 10,000 shares of Humacyte common stock in an open market or private transaction on August 20, 2026 at a price of $0.693 per share. Following this transaction, he directly owns 40,000 shares of Humacyte common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 10,000 shares
Net Buy
1 txn
Insider
Jones Keith Anthony
Role
Director
Bought
10,000 shs ($7K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 10,000 | $0.693 | $7K |
Holdings After Transaction:
Common Stock — 40,000 shares (Direct)
Key Figures
Shares purchased: 10,000 shares of Common Stock
Purchase price per share: $0.693 per share
Shares owned after transaction: 40,000 shares of Common Stock
3 metrics
Shares purchased
10,000 shares of Common Stock
Purchase reported on August 20, 2026
Purchase price per share
$0.693 per share
Price for the 10,000-share purchase on August 20, 2026
Shares owned after transaction
40,000 shares of Common Stock
Direct ownership following the reported purchase
Key Terms
Form 4, Common Stock, open market or private transaction
3 terms
Form 4 regulatory
"reported purchasing 10,000 shares of Humacyte common stock on Form 4"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Common Stock financial
"10,000 shares of Humacyte common stock in an open market"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
open market or private transaction financial
"purchase in an open market or private transaction on August 20, 2026"
FAQ
What insider transaction did Humacyte (HUMA) report for Keith Anthony Jones?
Humacyte director Keith Anthony Jones reported purchasing 10,000 shares of Humacyte common stock on August 20, 2026 in an open market or private transaction at $0.693 per share.
Was the Humacyte (HUMA) insider trade a purchase or a sale?
The reported Humacyte insider trade was a purchase. Director Keith Anthony Jones acquired 10,000 shares of Humacyte common stock at $0.693 per share in an open market or private transaction.
At what price did Keith Anthony Jones buy Humacyte (HUMA) stock?
Keith Anthony Jones bought Humacyte common stock at a price of $0.693 per share for 10,000 shares on August 20, 2026, according to the Form 4 filing.
Is the reported Humacyte (HUMA) insider ownership direct or indirect?
The Form 4 states that Keith Anthony Jones’ ownership of Humacyte common stock after the transaction, totaling 40,000 shares, is held as direct ownership.
AI-generated analysis. How Rhea-AI works. Not financial advice.
